PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
about
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.PSMA Theranostics: Current Status and Future Directions.
P2860
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
PSMA targeted radioligandthera ...... analysis of overall survival.
@en
PSMA targeted radioligandthera ...... analysis of overall survival.
@nl
type
label
PSMA targeted radioligandthera ...... analysis of overall survival.
@en
PSMA targeted radioligandthera ...... analysis of overall survival.
@nl
prefLabel
PSMA targeted radioligandthera ...... analysis of overall survival.
@en
PSMA targeted radioligandthera ...... analysis of overall survival.
@nl
P2093
P2860
P1476
PSMA targeted radioligandthera ...... e analysis of overall survival
@en
P2093
H Ahmadzadehfar
M Boegemann
M Eveslage
M Schäfers
P2860
P2888
P356
10.1007/S00259-017-3848-4
P577
2017-10-12T00:00:00Z